Korean study monitors prevenar 20 vaccine safety
NCT ID NCT06760208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is checking how safe the Prevenar 20 vaccine is once it's used in Korea. About 660 people aged 6 weeks and older who are prescribed the vaccine will get one dose. Researchers will track any side effects for 28 days after vaccination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Korea
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a two-drug combo better tame prostate trouble?
- New vaginal capsule aims to tackle stubborn bacterial vaginosis
- Tiny study checks if novel bacterium is safe for people
- New painkiller oliceridine tested against morphine in back surgery patients
- New online guide aids dementia caregivers in tough gun safety choices
- New supplement shows promise for stress and sleep in healthy adults